The use of a combination of mTOR inhibitor – rapamycin and AKT inhibitor – MK-2206 has been described by many research groups that reported a reduction of cell growth, blockade of cell cycle progression, and enhanced apoptosis in different melanoma models (humans, murine and canine) (Grazia et al. 2014). Here, AKT1 is linked to melanoma.